


## AC-262536

<b>Cat. No.:</b>	HY-122025		
<b>CAS No.:</b>	870888-46-3		
<b>Molecular Formula:</b>	C <sub>18</sub> H <sub>18</sub> N <sub>2</sub> O		
<b>Molecular Weight:</b>	278.35		
<b>Target:</b>	Androgen Receptor		
<b>Pathway:</b>	Vitamin D Related/Nuclear Receptor		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 50 mg/mL (179.63 mM; ultrasonic and warming and heat to 60°C)

Concentration	Mass			
	1 mg	5 mg	10 mg	
1 mM	3.5926 mL	17.9630 mL	35.9260 mL	
5 mM	0.7185 mL	3.5926 mL	7.1852 mL	
10 mM	0.3593 mL	1.7963 mL	3.5926 mL	

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (8.98 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (8.98 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 0.56 mg/mL (2.01 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

AC-262536 is a selective and non-steroidal androgen receptor modulators (SARMs) with beneficial anabolic effects. AC-262536 exhibits potent agonist activity at the androgen receptor, with an affinity in the low nanomolar range (1-10 nM)<sup>[1]</sup>.

#### In Vitro

AC-262536 dose-dependently inhibits dihydroxytestosterone (DHT)-induced proliferation of LNCaP. The effects are significant with 100 nM AC-262536 (%inhibition 47.2±12.2), and reaches a plateau with 1 μM treatment (%inhibition 50.7±7.6). Thus, AC-262536 can act as a functional antagonist in prostate cells<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## In Vivo

AC-262536 (3, 10, 30 mg/kg) reverses the luteinizing hormone (LH) spike in castrated rats<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (200-225 g) <sup>[1]</sup>
Dosage:	3, 10 and 30 mg/kg
Administration:	Administered subcutaneously; once daily for 14 consecutive days
Result:	Significantly decreased LH levels by about 40% at the 3 mg/kg dose. The ED <sub>50</sub> was determined to be 2.8 mg/kg. At the 10 and 30 mg/kg doses, the effects of AC-262536 were significantly stronger than Testosterone Propionate (TP) : 1.91±0.32 ng/mL and 1.53±0.34 ng/mL vs. 3.12±0.69 ng/mL, respectively.

## REFERENCES

[1]. Fabrice Piu, et al. Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator. J Steroid Biochem Mol Biol. 2008 Mar;109(1-2):129-37.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA